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S U M M A R Y
Objectives: The relationship between patient sex and the effectiveness of peginterferon alpha-2a and
ribavirin treatment in chronic hepatitis C (CHC) patients remains unclear. The aim of this study was to
investigate the impact of sex on virologic responses rates in genotype 1 CHC patients.
Methods: A matched retrospective cohort study of 630 genotype 1 patients treated with peginterferon
and ribavirin derived from our hospital database was conducted. These patients were divided into three
groups according to age: patients aged <40 years (n = 200), patients aged 40–50 years (n = 210), and
patients aged 51–60 years (n = 220). The rate of patients receiving 80% of the planned drug dose and
virologic response rates were compared between males and females in the three groups. Factors
inﬂuencing the sustained virologic response (SVR) were studied by multivariate analysis.
Results: In patients aged 51–60 years, the rate of female patients receiving 80% of the planned ribavirin
dose was signiﬁcantly lower than that of males (42.7%, 47/110 vs. 61.8%, 68/110; Chi-square = 8.035,
p = 0.005). In patients aged <40 years, the SVR rate of females was signiﬁcantly higher than that of males
(75%, 75/100 vs. 54%, 54/100; Chi-square = 9.630, p = 0.002); in patients aged 40–50 years, there was no
signiﬁcant difference in the SVR rate between males and females (50.5%, 53/105 vs. 54.3%, 57/105; Chi-
square = 0.305, p = 0.580); in patients aged 51–60 years, the SVR rate of females was signiﬁcantly lower
than that of males (33.6%, 37/110 vs. 48.2%, 53/110; Chi-square = 4.814, p = 0.028). In multivariate
logistic regression analysis, the independent factors associated with SVR in patients aged 51–60 years
were sex (p = 0.013), 80% of the planned ribavirin dose (p = 0.008), and the presence of a rapid virologic
response (p = 0.001).
Conclusions: In the group of patients aged <40 years, the SVR rate of females was higher than that of
males; in the group of patients aged 40–50 years, females and males shared similar SVR rates; in the
group of patients aged 51–60 years, the SVR rate of females was lower than that of males.
Crown Copyright  2011 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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Chronic hepatitis C (CHC) is a serious global health concern.
Despite a similar prevalence, the rates of progression of ﬁbrosis in
CHC differ signiﬁcantly between males and females. Clinical
observations show that chronic liver disease progresses more
rapidly to cirrhosis in males than females.1 The severity of ﬁbrosis
in CHC is also signiﬁcantly different between males and females.2
Recent data strongly suggest that estrogens and/or estrogen
receptors have an impact on the course of liver disease. A number
of studies suggest that the estrogen, at physiological levels,
presents an antiﬁbrogenic action probably through an antioxidant
effect, decreasing the levels of lipid peroxidation products in the
liver and blood, thus inhibiting the myoﬁbroblastic transformation* Corresponding author. Tel.: +86 0451 86605614.
E-mail address: lijiesun5234@yahoo.com.cn (L.-J. Sun).
1201-9712/$36.00 – see front matter . Crown Copyright  2011 Published by Elsevier 
doi:10.1016/j.ijid.2011.05.018of stellate cells and contributing to gender-associated differences
in relation to the development of ﬁbrosis.3 A decrease in estrogen
receptors, marked after the menopause, is reported to be
associated with increased lipid peroxidation and impaired
superoxide dismutase function, leading to increased susceptibility
to hepatic ﬁbrosis or hepatocellular carcinoma (HCC).4 There is
evidence for a potentially favorable effect on hepatic ﬁbrosis in
relation to the use of hormone replacement therapy (HRT) in
women with CHC after the menopause.5 On the other hand,
women are less tolerant to ribavirin owing to hemolytic side-
effects.6 In older female patients, lower average cumulative
exposure to ribavirin results in high relapse rates and low
sustained virologic response (SVR) rates.7 Therefore, older female
patients may have negative prognostic factors for SVR, such as
advanced ﬁbrosis or lower cumulative exposure to ribavirin.
Combination therapy with pegylated interferon (PEG-IFN) and
ribavirin is the current ﬁrst-line therapy used to eliminate
hepatitis C virus (HCV) in patients with CHC.8 IndependentLtd on behalf of International Society for Infectious Diseases. All rights reserved.
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pretreatment viral load, the absence of cirrhosis or ﬁbrosis, and
female gender.9 Age and sex may affect the efﬁcacy of antiviral
therapy. People aged over 40 years are progressively more
susceptible to faster rates of ﬁbrosis. The SVR rate is low in
patients with advanced liver ﬁbrosis. Data from a meta-analysis
and large, randomized, clinical trials of combination therapy with
PEG-IFNa plus ribavirin have shown that age older than 40 years is
an independent predictor of a reduced SVR.10 The inﬂuence of
gender on treatment with PEG-IFN and ribavirin is still under
debate. In a previous study, the response to IFN treatment was
shown to be better in women than in men.11 Sezaki and
colleagues12 have reported that response to combined PEG-IFN
and ribavirin is poorer in female than male patients with hepatitis
C who are aged >50 years, and that the low tolerance to ribavirin
and low estrogen levels in older women could be responsible for
their impaired response. Narciso-Schiavon et al. proved that the
rate of SVR did not differ between the genders.13 Kainuma et al.14
found no signiﬁcant differences between the sexes, and their data
suggest that age may be a more important factor than sex for
increasing the rate of SVR.
There remains a possibility that the SVR rate could be
inﬂuenced by age. Hence, there is the need for a comparison of
the response between men and women in different age groups. To
collect more convincing evidence of different therapeutic effects
between male and female patients, we utilized a well-designed
matched retrospective cohort study to control the bias of patient
selection.
2. Methods
2.1. Study population and study design
CHC patients were diagnosed by the presence of serum
antibodies to HCV, detectable serum HCV RNA, and compensated
liver disease. Patients were excluded if they had hepatitis A or B or
D or E, or HIV infection. Further exclusion criteria included
autoimmune disease, psychiatric disease, uncontrolled diabetes
mellitus, symptomatic cardiac or cardiovascular diseases, alcohol
intake greater than 20 g daily, and the presence of drug abuse.
Patients were ineligible if they had received interferon and/or
ribavirin previously. The neutrophil count had to be at least
1.5  109/l, platelet count >100  109/l, hemoglobin level >120 g/l
in women and >130 g/l in men, and serum creatinine levels had to
be <1.5 times the upper limit of normal. Decompensated liver
cirrhosis (bleeding, ascites, and encephalopathy) and HCC were
excluded in all patients by computed tomography (CT) and/or
magnetic resonance imaging (MRI) and/or elevated alpha-fetopro-
tein. Compensated cirrhosis was diagnosed by liver histology or
clinical data (CT images). Patients with compensated cirrhosis
typically exhibit enlargement of the hilar periportal space,
hypertrophy of the caudate lobe and the lateral segment of the
left lobe, and atrophy of the right lobe and medial segment of the
left lobe on CT images.
To evaluate the efﬁcacy of peginterferon and ribavirin in CHC
patients, a matched retrospective cohort study using data on
genotype 1 CHC patients derived from our database was
conducted. The database included 978 patients who fulﬁlled the
inclusion and exclusion criteria for the period January 2004 to
September 2009 at the Department of Infectious Diseases, Second
Afﬁliated Hospital, Harbin Medical University, China. Among the
978 patients, we selected 315 male and 315 female patients using
SAS v.8.2 software (SAS Institute, Cary, NC, USA); the match ratio
was 1:1. The trial was approved by the Ethics Committee according
to the Declaration of Helsinki. All patients gave written informed
consent before treatment.2.2. Serum HCV RNA and HCV genotyping
Serum antibodies to HCV were detected using a third-
generation HCV enzyme-linked immunosorbent assay (Ortho
Diagnostic Systems, Raritan, NJ, USA). Serum HCV RNA levels
were measured by a quantitative reverse-transcriptase PCR assay
(COBAS Amplicor HCV Monitor 2.0; Roche Diagnostic Systems,
Branchburg, NJ, USA) at baseline, at weeks 4, 12, and every 12
weeks thereafter during treatment, at the end of treatment, and at
week 24 of follow-up. The lower detection limit of the qualitative
assay is 100 copies/ml. The HCV genotype was determined by
restriction fragment length polymorphism (RFLP) of sequences
ampliﬁed in the 50 non-coding region.
2.3. Liver histology
Pretreatment liver biopsy specimens were analyzed for ﬁbrosis
according to METAVIR classiﬁcation on a scale of F0–F4 (F0, no
ﬁbrosis; F1, portal ﬁbrosis without septa; F2, portal ﬁbrosis with a
few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis).
2.4. Treatment regimen and dose modiﬁcations
The patients received 180 mg peginterferon alpha 2a (PEGASYS,
Hoffmann to Roche, Basel, Switzerland) subcutaneously once a
week plus daily ribavirin (1000 mg/day for weight <75 kg or
1200 mg/day for weight 75 kg) for 48 weeks. All subjects were
followed up for 24 weeks after cessation of therapy.
Dosage reduction of peginterferon alpha-2a and ribavirin
were advised for managing neutropenia, thrombocytopenia, and
anemia. The peginterferon alpha-2a dose was modiﬁed by a 45-
mg stepwise decrease to enhance adherence. When the patient’s
absolute neutrophil count (ANC) fell below 0.75  109/l, the
dose of peginterferon alpha-2a was reduced to 135 or 90 mg per
week; when the patient’s ANC fell below 0.5  109/l, peginter-
feron alpha-2a was temporarily discontinued. When the
patient’s platelet count fell below 50  109/l, the dose of
peginterferon alpha-2a was reduced to 90 mg per week; when
the patient’s platelet count fell below 25  109/l, peginterferon
alpha-2a was temporarily discontinued. The dose of ribavirin
was reduced by 200 mg/day when the patient’s hemoglobin
concentration fell below 100 g/l.15 Ribavirin was discontinued
when the patient’s hemoglobin concentration fell below 85 g/l.
Patients could receive peginterferon alpha-2a alone if ribavirin
was stopped. Restoration of the treatment was permitted if
laboratory abnormalities improved. The use of granulocyte
macrophage colony-stimulating factor (GM-CSF) was permitted
to manage hematologic adverse events. Erythropoietin (EPO)
was not used to manage anemia in this study, as the use of EPO
to manage IFN- and ribavirin induced anemia has not been
approved in China.
2.5. Observation indicators
Achievement of rapid virologic response (RVR), complete early
virologic response (cEVR), partial early virologic response (pEVR),
end-of-treatment virologic response (ETVR), and SVR of patients
was observed. RVR was deﬁned as undetectable serum HCV RNA
after 4 weeks of combination therapy. cEVR was deﬁned as HCV
RNA negative at week 12, but no RVR. pEVR was deﬁned as a 2
log10 drop in HCV RNA level from baseline at week 12, but no RVR
or cEVR. Patients with undetectable virus at the end of treatment
were considered to have achieved an ETVR. Relapse was deﬁned as
patients with undetectable HCV RNA at the end of treatment and
detectable HCV RNA during follow-up. Only patients with
undetectable virus at the end of treatment and again 24 weeks
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SVR.
Patients receiving 80% of the planned peginterferon alpha-2a
or ribavirin dose were recorded. The rate of patients receiving
80% of the planned peginterferon alpha-2a or ribavirin dose and
virologic response rates (RVR, cEVR, pEVR, ETVR, SVR, and relapse
rate) were compared between males and females in three age
groups (<40 years, 40–50 years, and 51–60 years).
2.6. Statistical analysis
The clinical, biochemical, and virologic characteristics of the
patients were expressed as mean  standard deviation. The
Student’s t-test was used when necessary for statistical comparison
of quantitative data, and the Chi-square test or Fisher’s exact test was
used when necessary for qualitative data. For all analyses a p-value of
<0.05 was considered statistically signiﬁcant.
Multiple logistic regression analysis was used to identify factors
related to SVR of CHC patients. In the multivariate logistic regression
model, the efﬁcacy of combination antiviral therapy (coded as 1,
with SVR, or 0, without SVR) was deﬁned as the dependent variable,
and several factors (sex, age, HCV RNA levels, alanine aminotrans-
ferase (ALT) levels, body weight, body mass index (BMI), hemoglobin
levels, white blood cell counts, platelet counts, histological ﬁbrosis,
80% of the planned peginterferon alpha-2a dose, 80% of the
planned ribavirin dose, and RVR) were deﬁned as independent
variables. Variables that achieved statistical signiﬁcance in the
univariate analysis (p-value <0.05) were subsequently included in a
logistic regression analysis. Selection of variables was based on a
stepwise regression analysis using a forward selection method. All
analyses were performed using statistical software package SPSS,
version 10.0 (SPSS Inc., Chicago, IL, USA).Table 1
Characteristics of 630 genotype 1 chronic hepatitis C patients at baseline
Group n Age
(years)
ALT
(U/l)
HCV RNA
(log copies/ml)
PLT
(109/l)
WBC
(109
Patients aged <40 years
Male 100 33.5  6.5 94  18 6.0  1.4 172  38 5.3  1
Female 100 33.8  6.7 92  19 6.1  1.3 170  37 5.2  1
Patients aged 40–50 years
Male 105 45.8  3.4 97  20 6.2  1.5 165  30 4.9  1
Female 105 46.0  3.5 98  21 6.3  1.6 164  31 5.0  1
Patients aged 51–60 yearsa
Male 110 55.7  5.8 85  16 6.1  1.4 159  24 4.7  0
Female 110 56.0  5.9 84  17 6.2  1.5 149  25 4.4  0
Results are mean  standard deviation. ALT, alanine aminotransferase; HCV, hepatitis C 
hemoglobin; BMI, body mass index.
a In patients aged 51–60 years: PLT: t = 3.026, p < 0.05; WBC: t = 2.613, p < 0.05; Hb: t =
square = 5.783, p = 0.016.
Table 2
Comparison of the rate of patients receiving 80% of the planned drug dose between 
Male 
Patients aged <40 years
80% of planned peginterferon dose 90% (90/100) 
80% of planned ribavirin dose 88% (88/100) 
Patients aged 40–50 years
80% of planned peginterferon dose 83.8% (88/105) 
80% of planned ribavirin dose 79.0% (83/105) 
Patients aged 51–60 years
80% of planned peginterferon dose 74.5% (82/110) 
80% of planned ribavirin dose 61.8% (68/110) 3. Results
3.1. Characteristics of patients in the three study groups at baseline
The patients were divided into three groups according to age:
patients aged <40 years (n = 200), patients aged 40–50 years
(n = 210), and patients aged 51–60 years (n = 220). Liver biopsy
was performed in 91 patients (45.5%) aged <40 years, 96 patients
(45.7%) aged 40–50 years, and 100 patients (45.5%) aged 51–60
years. The remaining patients refused a liver biopsy; they were
diagnosed by clinical data. Compensated cirrhosis (Child–Pugh
score <6) was present in 51 patients.
The demographic, virologic, and clinical characteristics were
similar in the male and female patients (Table 1), except that in the
group of patients aged 51–60 years, male patients had a signiﬁcantly
higher mean hemoglobin level (142  15 vs. 135  12 g/l, t = 3.822, p
< 0.05), mean white blood cell count (4.7  0.8 vs. 4.4  0.9  109/l,
t = 2.613, p < 0.05), and mean platelet count (159  24 vs.
149  25  109/l, t = 3.026, p < 0.05) than female patients; also,
histological ﬁbrosis was more advanced in female patients than male
patients (22/12/16 vs. 38/6/6, Chi-square = 10.812, p = 0.004) and
compensated cirrhosis was more frequent in female patients than male
patients (19/60 vs. 8/60, Chi-square = 5.783, p = 0.016).
3.2. Comparison of the rate of patients receiving 80% of the planned
drug dose between males and females in the three age groups
The rates of male and female patients receiving 80% of the
planned drug dose in the different age groups were compared
(Table 2). There were no signiﬁcant differences between male and
female patients in the rates receiving 80% of the planned
peginterferon alpha-2a dose in the three age groups. In the group of/l)
Hb
(g/l)
Body weight
(kg)
BMI
(kg/m2)
Fibrosis
(F0–2/F3/F4)
No. of
patients with
compensated
cirrhosis
.2 148  19 64.2  10.5 23.4  2.8 39/4/3 4
.1 147  18 63.6  10.4 23.2  2.7 38/4/3 5
.0 145  18 63.6  10.3 23.3  3.0 40/2/6 7
.1 144  17 63.3  10.4 23.1  2.9 39/3/6 8
.8 142  15 63.0  10.3 23.0  2.5 38/6/6 8
.9 135  12 62.2  10.1 22.8  2.4 22/12/16 19
virus; RNA, ribonucleic acid; PLT, platelet count; WBC, white blood cell count; Hb,
 3.822, p < 0.05; ﬁbrosis: Chi-square = 10.812, p = 0.004; compensated cirrhosis: Chi-
males and females in the different age groups
Female p-Value
92% (92/100) Chi-square = 0.244, p = 0.621
85% (85/100) Chi-square = 0.385, p = 0.535
81.0% (85/105) Chi-square = 0.295, p = 0.587
76.2% (80/105) Chi-square = 0.247, p = 0.619
70% (77/110) Chi-square = 0.567, p = 0.451
42.7% (47/110) Chi-square = 8.035, p = 0.005
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the planned ribavirin dose was signiﬁcantly lower in females than
in males (42.7%, 47/110 vs. 61.8%, 68/110; Chi-square = 8.035,
p = 0.005).
3.3. Comparison of the rate of patients receiving GM-CSF between
males and females in the three age groups
One hundred and thirty-one patients received GM-CSF during
treatment. In patients aged <40 years, the rate of patients receiving
GM-CSF was 9% (9/100) in male patients and 12% (12/100) in
female patients, showing no signiﬁcant difference (Chi-
square = 0.479, p = 0.489). In patients aged 40–50 years, the rate
of patients receiving GM-CSF was 14.4% (15/105) in male patients
and 17.1% (18/105) in female patients, showing no signiﬁcant
difference (Chi-square = 0.324, p = 0.569). In patients aged 51–60
years, the rate of patients receiving GM-CSF was signiﬁcantly
higher in females than in males (42.7%, 47/110 vs. 27.3%, 30/110;
Chi-square = 5.774, p = 0.005).
3.4. Comparison of virologic response rates between males and
females in the three age groups
In the group of patients aged <40 years, the pEVR rate of males
was signiﬁcantly higher than that of females (38%, 38/100 vs. 17%,
17/100; Chi-square = 11.060, p = 0.001); there was no signiﬁcant
difference in the ETVR rate between males and females (80%, 80/Table 5
Comparison of virologic response rates between male and female patients aged 51–60
Group n On-treatment virologic response 
RVR cEVR pEVRa
Male 110 18.2% (20/110) 36.4% (40/110) 26.4% (29/110) 
Female 110 15.5% (17/110) 18.2% (20/110) 46.4% (51/110) 
RVR, rapid virologic response; cEVR, complete early virologic response; pEVR, partial e
virological response.
a pEVR: Chi-square = 9.507, p = 0.002.
b ETVR: Chi-square = 0.218, p = 0.640.
c Relapse rate: Chi-square = 5.045, p = 0.025.
d SVR: Chi-square = 4.814, p = 0.028.
Table 4
Comparison of virologic response rates between male and female patients aged 40–50
Group n On-treatment virologic response 
RVR cEVR pEVR 
Male 105 16.2% (17/105) 28.6% (30/105) 39.0% (41/105) 
Female 105 19.0% (20/105) 33.3% (35/105) 27.6% (29/105) 
RVR, rapid virologic response; cEVR, complete early virologic response; pEVR, partial e
virological response.
a ETVR: Chi-square = 0.283, p = 0.594.
b Relapse rate: Chi-square = 0.109, p = 0.741.
c SVR: Chi-square = 0.305, p = 0.580.
Table 3
Comparison of virologic response rates between male and female patients aged <40 y
Group n On-treatment virologic response 
RVR cEVR pEVRa
Male 100 16% (16/100) 30% (30/100) 38% (38/100) 
Female 100 20% (20/100) 48% (48/100) 17% (17/100) 
RVR, rapid virologic response; cEVR, complete early virologic response; pEVR, partial e
virological response.
a pEVR: Chi-square = 11.060, p = 0.001.
b ETVR: Chi-square = 0.866, p = 0.352.
c Relapse rate: Chi-square = 10.388, p = 0.001.
d SVR: Chi-square = 9.630, p = 0.002.100 vs. 85%, 85/100; Chi-square = 0.866, p = 0.352); the relapse
rate of males was signiﬁcantly higher than that of females (32.5%,
26/80 vs. 11.8%, 10/85; Chi-square = 10.388, p = 0.001); the SVR
rate of females was signiﬁcantly higher than that of males (75%, 75/
100 vs. 54%, 54/100; Chi-square = 9.630, p = 0.002) (Table 3).
In the group of patients aged 40–50 years, there was no
signiﬁcant difference in the ETVR rate (80%, 84/105 vs. 82.9%, 87/
105; Chi-square = 0.283, p = 0.594), the relapse rate (36.9%, 31/84
vs. 34.5%, 30/87; Chi-square = 0.109, p = 0.741), or the SVR rate
(50.5%, 53/105 vs. 54.3%, 57/105; Chi-square = 0.305, p = 0.580)
between males and females (Table 4).
In the group of patients aged 51–60 years, the pEVR rate of
males was signiﬁcantly lower than that of females (26.4%, 29/110
vs. 46.4%, 51/110; Chi-square = 9.507, p = 0.002); the relapse rate
of males was signiﬁcantly lower than that of females (36.9%, 31/84
vs. 54.3%, 44/81; Chi-square = 5.045, p = 0.025); there was no
signiﬁcant difference in the ETVR rate between males and females
(76.4%, 84/110 vs. 73.6%, 81/110; Chi-square = 0.218, p = 0.640);
the SVR rate of females was signiﬁcantly lower than that of males
(33.6%, 37/110 vs. 48.2%, 53/110; Chi-square = 4.814, p = 0.028)
(Table 5).
3.5. Comparison of SVR rates between males and females in patients
receiving 80% of the planned drug dose
To exclude the effects of drug dose reductions on virologic
response rates, we further investigated the SVR rates between years
ETVRb Relapse ratec SVRd
No RVR or EVR
19.1% (21/110) 76.4% (84/110) 36.9% (31/84) 48.2% (53/110)
20% (22/110) 73.6% (81/110) 54.3% (44/81) 33.6% (37/110)
arly virologic response; ETVR, end of treatment virologic response; SVR, sustained
 years
ETVRa Relapse rateb SVRc
No RVR or EVR
16.2% (17/105) 80% (84/105) 36.9% (31/84) 50.5% (53/105)
20% (21/105) 82.9% (87/105) 34.5% (30/87) 54.3% (57/105)
arly virologic response; ETVR, end of treatment virologic response; SVR, sustained
ears
ETVRb Relapse ratec SVRd
No RVR or EVR
16% (16/100) 80% (80/100) 32.5% (26/80) 54% (54/100)
15% (15/100) 85% (85/100) 11.8% (10/85) 75% (75/100)
arly virologic response; ETVR, end of treatment virologic response; SVR, sustained
Table 6
Univariate analysis of factors inﬂuencing SVR in chronic hepatitis C patients
Variable With an SVR (n = 329) Without an SVR (n = 301) p-Value
Sex (male/female) Chi-square = 6.167, p = 0.046
Patients aged <40 years 54/75 46/25
Patients aged 40–50 years 53/57 52/48
Patients aged 51–60 years 53/37 57/73
Age (years), mean  SD 46.8  4.7 49.5  5.4 Chi-square = 6.670, p = 0.003
Presence of RVR 90/239 20/281 Chi-square = 46.786, p < 0.001
HCV RNA (log10 copies/ml) 5.5  0.8 6.4  0.9 t = 13.382, p = 0.001
ALT level (U/l) 92  16 94  17 t = 1.517, p = 0.120
Body weight (kg) 63.4  10.4 63.8  10.6 t = 0.477, p = 0.439
BMI (kg/m2) 23.3  3.0 23.1  2.9 t = 0.850, p = 0.121
Platelet count (109/l) 167  30 162  29 t = 2.126, p = 0.040
White blood cell count (109/l) 4.8  1.2 4.7  1.1 t = 1.090, p = 0.363
Hemoglobin level (g/l) 143  18 141  20 t = 1.289, p = 0.171
80% of planned peginterferon alfa-2a dose (yes/no) 274/55 240/61 Chi-square = 1.318, p = 0.251
80% of planned ribavirin dose (yes/no) 255/74 196/105 Chi-square = 11.866, p = 0.001
Histological ﬁbrosis (F0–2/F3–4) 144/32 72/39 Chi-square = 10.508, p = 0.001
SVR, sustained virologic response; SD, standard deviation; RVR, rapid virologic response; HCV, hepatitis C virus; RNA, ribonucleic acid; ALT, alanine aminotransferase; BMI,
body mass index.
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peginterferon alpha-2a or ribavirin dose. In patients aged 51–60
years, 159 patients received 80% of the planned peginterferon
alpha-2a dose and the SVR rate of females was signiﬁcantly lower
than that of males (42.9%, 33/77 vs. 61.0%, 50/82; Chi-
square = 5.225, p = 0.022); 115 patients received 80% of the
planned ribavirin dose and the SVR rate of females was
signiﬁcantly lower than that of males (38.3%, 18/47 vs. 64.7%,
44/68; Chi-square = 7.800, p = 0.005).
3.6. The role of RVR in predicting SVR
The SVR rate (81.8%, 90/110) in patients who had achieved RVR
was signiﬁcantly higher than in those who had not (46.0%, 239/
520) (Chi-square = 46.786, p < 0.001). In patients aged <40 years,
the positive predictive value of RVR in males was 81.3% (13/16) and
in females was 80% (16/20), showing no signiﬁcant difference
between them (Chi-square = 0.009, p = 0.925). In patients aged 40–
50 years, the positive predictive value of RVR in males was 82.4%
(14/17) and in females was 85% (17/20), showing no signiﬁcant
difference between them (Chi-square = 0.047, p = 0.828). In
patients aged 51–60 years, the positive predictive value of RVR
in males was 80% (16/20) and in females was 82.4% (14/17),
showing no signiﬁcant difference between them (Chi-
square = 0.033, p = 0.855).
3.7. Predictive factors associated with SVR in CHC patients
Predictive factors associated with SVR in CHC patients were
studied. In univariate analysis, age (p = 0.003), HCV RNA levels
(p = 0.001), sex (p = 0.046), platelet counts (p = 0.040), histological
ﬁbrosis (p = 0.001), 80% of the planned ribavirin dose (p = 0.001),
and the presence of RVR (p < 0.001) were associated with SVR
(Table 6). However, in multivariate logistic regression analysis, theTable 7
Multivariate logistic regression analysis of factors inﬂuencing SVR in chronic hepatitis
Variable Coefﬁcient Ch
Age 1.523 4
Presence of RVR 2.103 15
Sex 1.123 12
HCV RNA levels 1.314 3
Histological ﬁbrosis 1.754 2
80% of planned ribavirin dose 2.431 11
Platelet count 1.017 2
SVR, sustained virologic response; OR, odds ratio; CI, conﬁdence interval; RVR, rapid vindependent factors associated with SVR were age (p = 0.015), sex
(p = 0.002), 80% of the planned ribavirin dose (p = 0.006), and the
presence of RVR (p = 0.001) (Table 7).
3.8. Predictive factors associated with SVR in patients aged 51–60
years
To identify patients aged 51–60 years who may beneﬁt from
combination therapy, we determined factors associated with SVR.
In univariate analysis, sex (p = 0.028), HCV RNA levels (p = 0.009),
histological ﬁbrosis (p = 0.033), 80% of the planned ribavirin dose
(p = 0.029), and the presence of RVR (p < 0.001) were associated
with SVR (Table 8). However, in multivariate logistic regression
analysis, the independent factors associated with SVR were sex
(p = 0.013), 80% of the planned ribavirin dose (p = 0.008), and
presence of RVR (p = 0.001) (Table 9).
4. Discussion
It is notable that not only age but also sex might play a role in
inﬂuencing the efﬁcacy of treatment in patients with CHC. To date,
the difference in response to treatment in patients with CHC
according to gender is controversial.11–14 The greatest physiologi-
cal change in women with increasing age is a decreased serum
concentration of estrogen after they enter the menopause.16
During the perimenopause (from age 40 years), ovulation can be
erratic, and plasma gonadotropin levels frequently reach meno-
pausal levels, even when plasma estrogen levels are within the
menstrual range.17 Experimental data suggest that estrogens may
have an antiﬁbrotic effect. The antiviral therapeutic effects
decrease with aging in female patients. Therefore, we evaluated
the effect of gender on the treatment of CHC patients categorized
by age. C patients
i-square OR (95% CI) p-Value
.931 4.586 (2.104–5.754) 0.015
.167 8.191 (4.186–9.983) 0.001
.005 3.074 (2.103–4.756) 0.002
.048 3.721 (2.403–4.996) 0.063
.617 5.778 (2.586–7.998) 0.109
.001 11.370 (5.279–16.025) 0.006
.566 2.765 (2.000–5.016) 0.095
irologic response; HCV, hepatitis C virus; RNA, ribonucleic acid.
Table 8
Univariate analysis of factors inﬂuencing SVR in patients aged 51–60 years
Variable With an SVR (n = 90) Without an SVR (n = 130) p-Value
Sex (male/female) 53/37 57/73 Chi-square = 4.814, p = 0.028
Presence of RVR 30/60 7/123 Chi-square = 29.695, p < 0.001
HCV RNA (log copies/ml) 5.8  0.9 6.4  1.0 t = 4.644, p = 0.009
ALT level (U/l) 91  18 93  17 t = 0.829, p = 0.342
Age (years), mean  SD 55.4  4.5 55.8  4.4 t = 0.654, p = 0.653
Body weight (kg) 62.5  10.2 62.4  10.1 t = 0.068, p = 0. 956
BMI (kg/m2) 22.9  2.6 22.7  2.8 t = 0.544, p = 0.237
80% of planned peginterferon alfa-2a dose (yes/no) 64/26 95/35 Chi-square = 0.103, p = 0.749
80% of planned ribavirin dose (yes/no) 55/35 60/70 Chi-square = 4.769, p = 0.029
Histological ﬁbrosis (F0–2/F3–4) 37/16 23/24 Chi-square = 4.523, p = 0.033
Platelet count (109/l) 158  27 155  26 t = 0.823, p = 0.473
White blood cell count (109/l) 4.4  0.9 4.2  0.8 t = 1.695, p = 0.085
Hemoglobin level (g/l) 140  17 138  16 t = 0.879, p = 0.249
SVR, sustained virologic response; RVR, rapid virologic response; HCV, hepatitis C virus; RNA, ribonucleic acid; ALT, alanine aminotransferase; SD, standard deviation; BMI,
body mass index.
Table 9
Multivariate logistic regression analysis of factors inﬂuencing SVR in patients aged 51–60 years
Variable Coefﬁcient Chi-square OR (95% CI) p-Value
Presence of RVR 2.001 14.003 7.396 (4.947–9.998) 0.001
HCV RNA levels (log copies/ml) 1.553 3.082 4.726 (2.003–5.847) 0.072
Sex 1.335 4.589 3.799 (2.009–5.978) 0.013
80% of planned ribavirin dose 2.534 9.856 12.604 (4.853–17.135) 0.008
Histological ﬁbrosis 1.210 1.756 3.353 (0.956–5.867) 0.282
SVR, sustained virologic response; OR, odds ratio; CI, conﬁdence interval; RVR, rapid virologic response; HCV, hepatitis C virus; RNA, ribonucleic acid.
J.-W. Yu et al. / International Journal of Infectious Diseases 15 (2011) e740–e746 e745Our study showed that the SVR rate decreased signiﬁcantly
with age in female patients with genotype 1 CHC, and was
markedly reduced in patients aged 51–60 years. Our study found
that in patients aged <40 years, the SVR rate in females was higher
than that in males. The favorable therapeutic effect may be related
to high levels of estrogen in these women. It has been proposed
that estrogen may suppress hepatic ﬁbrosis through an effect that
depends on its hepatic tissue receptors, and improve the antiviral
therapy.18
To identify factors that predict SVR among patients aged 51–60
years (hard-to-treat population), we studied the factors inﬂuenc-
ing SVR by multiple logistic regression analysis and found some
independent factors associated with SVR, such as sex, 80% of the
planned ribavirin dose, and the presence of RVR.
Ribavirin accumulates in erythrocytes and induces hemolytic
anemia. Older female patients are less resistant to the anemia
induced by ribavirin.19 In our study, in patients aged 51–60 years,
female patients had a signiﬁcantly lower mean hemoglobin level
than male patients at baseline, which would have been responsi-
ble for the lower rate of patients receiving 80% of the planned
ribavirin dose in women than in men. To exclude the effects of
drug dose reductions on virologic response rates, we further
investigated the SVR rates in male and female patients receiving
80% of the planned peginterferon alpha-2a or ribavirin dose. We
found that the SVR rate of female patients aged 51–60 years was
still signiﬁcantly lower than that of male patients. We found that
these female patients had signiﬁcantly lower mean white blood
cell counts and platelet counts than male patients and that the
ﬁbrosis stage was more advanced in female patients than in male
patients.
We showed that older women have a lower SVR rate and higher
relapse rate than men. The lower cumulative ribavirin exposure
and decreased antiﬁbrotic effects of low estrogen levels in female
patients aged >50 years would produce a lower response to PEG-
IFN and ribavirin. The lower cumulative drug exposure to ribavirin
due to a higher incidence of hemolytic anemia in older female
patients may ﬁrst explain the higher relapse rate and lower SVR.Increasing rates of bridging ﬁbrosis in women with age may also
play a role in reducing the sustained response to combination
therapy.
In this study, erythropoietin (EPO) was not used to manage
anemia. Recently, EPO therapy has been shown to reduce the risk
and magnitude of anemia, and provide space for a higher ribavirin
dose.20 The use of EPO to manage IFN- and ribavirin-induced anemia
has not been approved in China. It would be useful to study whether
or not this intervention improves the efﬁcacy of treatment.
We found that compared with male patients, the pEVR and
relapse rate in older female patients with HCV genotype 1 were high.
For elderly patients with pEVR, 48-week combination treatment was
not enough to clear HCV. These patients with pEVR might beneﬁt
from prolongation of therapy from 48 to 72 weeks. This beneﬁt could
derive from a lower relapse rate after the extension of the plasma
HCV RNA-free period in slower responders.
The assessment of virological response at treatment week 4 is a
simple and reliable tool for identifying patients most likely to
achieve an SVR.21We found that RVR could predict SVR in a similar
way in both male and female patients. Attainment of an RVR is the
most powerful predictor of SVR, irrespective of sex.
In conclusion, this study indicates that for genotype 1 CHC, in
patients aged <40 years the SVR rate in females is higher than that
in males; in patients aged 40–50 years, similar SVR rates are found
in males and females; and in patients aged 51–60 years, the SVR
rate in females is lower than that in males. Our study was
retrospective, and the number of patients in the study population
was limited. Thus, a multicenter, randomized and controlled trial is
needed to further validate these conclusions.
Conﬂict of interest: No beneﬁts in any form have been received or
will be received from a commercial party related directly or
indirectly to the subject of this article.
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